Ticker
$BMRN
1 catalyst touching BMRN in the last 60 days, newest first, each with the price move that followed.
- 68
BioMarin posts $320M pre-tax Alesta acquisition charge for 2026
BioMarin completed the Alesta Therapeutics acquisition on August 31, 2026, and disclosed $283 million in in-process R&D (IPR&D) expense for Q3 2026 and $320 million total pre-tax charges for full-year 2026, representing approximately $1.55 unfavorable EPS impact. Large one-time acquisition charges reduce near-term reported earnings, though the long-term strategic rationale depends on Alesta's pipeline value not yet apparent in this filing.
BMRN ▼SEC 8-K · 6 Oct 2026, 20:22 UTC
Information only. AURA does not give buy or sell recommendations.